Separately, Zacks Investment Research lowered shares of Kazia Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd.
NASDAQ KZIA traded up $0.07 during mid-day trading on Monday, hitting $3.22. The company’s stock had a trading volume of 329 shares, compared to its average volume of 4,852. Kazia Therapeutics has a 52-week low of $2.04 and a 52-week high of $4.27. The stock’s fifty day simple moving average is $3.15 and its two-hundred day simple moving average is $2.92. The firm has a market capitalization of $20.72 million, a P/E ratio of -3.32 and a beta of 1.63.
A hedge fund recently bought a new stake in Kazia Therapeutics stock. Citadel Advisors LLC purchased a new stake in Kazia Therapeutics Ltd (NASDAQ:KZIA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,473 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 0.33% of Kazia Therapeutics as of its most recent filing with the Securities & Exchange Commission. 3.66% of the stock is owned by hedge funds and other institutional investors.
About Kazia Therapeutics
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.
See Also: What is the market perform rating?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.